Zimmer Biomet price target lowered to $119 from $152 at Wells Fargo

Wells Fargo lowered the firm’s price target on Zimmer Biomet to $119 from $152 and keeps an Equal Weight rating on the shares. The firm notes Q3 sales were roughly in line, but EPS was ahead. 2023 sales and EPS guidance was also maintained, Wells adds.